<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513197</url>
  </required_header>
  <id_info>
    <org_study_id>NODAP</org_study_id>
    <nct_id>NCT04513197</nct_id>
  </id_info>
  <brief_title>NEW ONSET ENDOCRINE DYSFUNCTION AFTER ACUTE PANCREATITIS</brief_title>
  <acronym>APPDM</acronym>
  <official_title>NEW ONSET ENDOCRINE DYSFUNCTION AFTER ACUTE PANCREATITIS(PANCREATICOGENIC DIABETES MILLETUS - TYPE 3C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Institute of Gastroenterology, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asian Institute of Gastroenterology, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIMS AND OBJECTIVES&#xD;
&#xD;
        1. To evaluate whether acute pancreatitis results in increased endocrine dysfunction or&#xD;
           not?&#xD;
&#xD;
        2. To evaluate whether severity of acute pancreatitis have an impact on the development of&#xD;
           endocrine dysfunction or not?&#xD;
&#xD;
      1.4 MATERIALS AND METHODS:- Definitions … 1) Acute pancreatitis…..Acute pancreatitis is best&#xD;
      defined clinically by a patient presenting with 2 of the following 3 criteria: (1)&#xD;
      symptoms(e.g., epigastric pain) consistent with pancreatitis, (2) a serum amylase or lipase&#xD;
      level greater than 3 times the laboratory's upper limit of normal, and (3) radiologic imaging&#xD;
      consistent with pancreatitis, usually using CT or MRI.The AtlantaCriteria revision of 2012&#xD;
      classifies severity as mild, moderately severe, or severe. Mild acute pancreatitis has no&#xD;
      organ failure, no local or systemic complications.Moderately-severe acute pancreatitis is&#xD;
      defined by the presence of transient organ failure (lasting &lt;48 hours) and/or local&#xD;
      complications.Severe acute pancreatitis is defined by persistent organ failure (lasting &gt;48&#xD;
      hours). Local complications include peripancreatic fluid collections, pancreatic and&#xD;
      peripancreatic necrosis (sterile or infected), pseudocyst, and walled-offnecrosis (sterile or&#xD;
      infected) .&#xD;
&#xD;
      Prediabetes/Diabetes….Prediabetes is defined by fasting blood glucose (FBG ≥(100 mg/dL) and&#xD;
      &lt;(126 mg/dL),and/or 2 h oral glucose tolerance test (OGTT) criteria as &gt;/ (140 mg/dL) and &lt;&#xD;
      (200 mg/dL)) or HbA1c of 5.7% to 6.4%. DM is defined as (FBG ≥ (126 mg/dL) or 2 hOGTT ≥ (200&#xD;
      mg/dL)or HbA1c value&gt;/ 6.5% ,treatment with insulin, oral hypoglycaemic agents or specific&#xD;
      dietary management. Diagnosis of diabetes in asymptomatic patients is established by presence&#xD;
      of abnormal test results in 2 out of 3 parameters used(FBG,OGTT or HbA1c) or if only one test&#xD;
      result is abnormal ,needs to be confirmed on next day or few days later by repeat testing of&#xD;
      the specific parameter.&#xD;
&#xD;
      Study design :- Single center ,prospective cohort study performed at a tertiary care centre&#xD;
      (Asian institute of gastroenterology , Hyderabad) from Feb 2019 to May 2020.&#xD;
&#xD;
      Participant recruitment procedures…. Patient enrollment from Feb 2019 to May 2019 &amp; follow up&#xD;
      of each case upto 1 year, upto May 2020(1 year follow up).&#xD;
&#xD;
      Primary outcome-Development of endocrine dysfunction (diabetes &amp; prediabetes) after acute&#xD;
      pancreatitis Secondary outcomes-Whether severity of acute pancreatitis correlate with&#xD;
      development of diabetes &amp; prediabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODOLOGY: Patients of acute pancreatitis will be screened as per inclusion/exclusion&#xD;
      criteria and patients with first episode of acute pancreatitis who meet the ATLANTA&#xD;
      definition, will be graded for severity as per Modified Marshall criteria. Control group for&#xD;
      the study will include nondiabetic /non prediabetic volunteers who come to OPD for master&#xD;
      health check up or who are being suspected to have functional syndromes like functional&#xD;
      dyspepsia or irritable bowel syndrome.The study will be a prospective cohort study in which&#xD;
      initial recruitment will be for 4 months from Feb 2019 to May 2019, &amp; recruited patients will&#xD;
      be followed for a period of 1 year each from the period of recruitment, and as such the study&#xD;
      is expected to complete by May 2020. On admission in addition to routine blood investigations&#xD;
      , specific investigations for acute pancreatitis will be done(complete details in proforma)&#xD;
      which include serum amylase ,serum lipase, USG abdomen, CECT abdomen(after 72hrs of onset of&#xD;
      acute pancreatitis) will be done to assess for pancreatic necrosis. Blood sugar (fasting,&#xD;
      postprandial) &amp; HBA1c will be done on admission to evaluate the diabetic status of the&#xD;
      patient. C peptide and Fasting insulin levels which will help assess the insulin resistance&#xD;
      will be done at onset only in these patients .Control group will be assessed clinically and&#xD;
      only clinically relevant investigations in addition to blood sugar (fasting, postprandial) &amp;&#xD;
      HBA1c will be done at initiation &amp; at 6months &amp; 1 year of follow up(follow up will be via&#xD;
      telephonic communication or if possible in person) On follow up at 2months , 6months &amp; 12&#xD;
      months patients will be reassessed either in person (if possible) or via telephonic&#xD;
      communication for endocrine dysfunction , which will be assessed by simple and routine tests&#xD;
      as mentioned ( Blood sugar-fasting, postprandial &amp; HbA1c).Controls will be clinically&#xD;
      assessed and if clinically stable and asymptomatic will be assessed for diabetic status only&#xD;
      with Blood sugar (fasting, postprandial) &amp; HBA1c at initiation &amp; subsequently at 6 months and&#xD;
      1 year end.&#xD;
&#xD;
      Statistical analysis :Data will be collected using a structured study proforma. Data will be&#xD;
      put in MS EXCEL for further analysis .Results will be expressed as mean(SD), median (IQR) for&#xD;
      continuous variables and percentage for categorical variables etc. Appropriate parametric and&#xD;
      non parametric will be applied. SPSS (21st version) will be used for statistical analyses.&#xD;
&#xD;
      Primary outcome…. To estimate incidence of endocrinopathy (diabetes &amp; prediabetes)among Acute&#xD;
      Pancreatitis patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of endocrine dysfunction (diabetes &amp; prediabetes) after acute pancreatitis</measure>
    <time_frame>1 year</time_frame>
    <description>Prediabetes/Diabetes is defined by fasting blood glucose (FBG ≥(100 mg/dL),HbA1c value&gt;/ 6.5% ,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2) To evaluate whether severity of acute pancreatitis have an impact on the development of endocrine dysfunction or not?</measure>
    <time_frame>72 hours</time_frame>
    <description>Severity of acute pancreatitis can be done based on elevated serum amylase and lipase levels.normal range of amylase level is( 28-100 units U/I) more than 3 times of normal range indicated acute pancreatitis, normal range of lipase is (5.6-51.3) more than 3 times of normal range leads to acute pancreatitis.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Endocrine System Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Required sample size is 90 subjects with 80% power and 0.05 as type 1 error.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1 )Ist episode of acute pancreatitis. 2) Non diabetic or non pre diabetic as per American&#xD;
        Diabetes Association criteria .&#xD;
&#xD;
        3) Age &gt;18yrs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute pancreatitis cases who die within 1 month of hospitalization.&#xD;
&#xD;
          2. Recurrent acute pancreatitis&#xD;
&#xD;
          3. Chronic pancreatitis.&#xD;
&#xD;
          4. Previous diagnosed diabetes or prediabetes&#xD;
&#xD;
          5. Any malignancy&#xD;
&#xD;
          6. Age &lt;18yrs&#xD;
&#xD;
          7. Pregnant females or lactating women.&#xD;
&#xD;
          8. Chronic diarrhea, intestinal tuberculosis or Crohns disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr MANU TANDAN, MBBS MD DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Institute of Gastroenterology, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>WAHID AKBAR LONE, MBBS MD</last_name>
    <phone>7006102770</phone>
    <email>wahidakbar333@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>RAJESH GOUD MARAGONI, M.PHARM, MBA</last_name>
    <phone>9705053550</phone>
    <email>rajeshgoud761@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology/AIG Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Mohan Ramchandani, MBBS MD DM</last_name>
      <phone>04023378888</phone>
      <phone_ext>802</phone_ext>
      <email>ramchandanimohan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Institute of Gastroenterology, India</investigator_affiliation>
    <investigator_full_name>Mohan Ramchandani</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

